Clinical Trial Update: Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating dose confirmation and safety of crizanlizumab in pediatric sickle cell disease patients; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• ADAKVEO (crizanlizumab)
• Crizanlizumab (crizanlizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sickle Cell Disease (SCD) | Phase 2 | Status: COMPLETED | Results posted: 2025-07-20